Compare Abbott Laboratories (ABT) vs Innovative Industrial Properties Inc (IIPR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Innovative Industrial Properties Inc — how do they compare? Abbott Laboratories trades at $95.38 (market cap $166.94B), while Innovative Industrial Properties Inc trades at $62.64 (market cap $1.79B). The key difference: Abbott Laboratories is far larger — about 93.3× Innovative Industrial Properties Inc's market cap, and Innovative Industrial Properties Inc pays the higher dividend (12.3%). Which is the better fit depends on your goals.
| ABT | IIPR | |
|---|---|---|
Market Cap | $166.94B | $1.79B |
Sector | Health | Real Estate |
52-Week High | $136.62 | $63.40 |
52-Week Low | $82.57 | $44.58 |
Enterprise Value | $193.69B | $2.18B |
Dividend Yield | 2.63% | 12.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
IIPR trades at $61.81, down 2.51% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported a Q1 2026 EPS beat of $1.88 versus $1.07 expected, though revenue has declined from $310M in 2023 to $266M in 2025. Recent news highlights progress on cannabis rescheduling as a potential tailwind and the declaration of a $1.90 dividend for Q2 2026.
The outlook is mixed; a high dividend yield and low P/E of 15.78 offer value, but declining revenue and negative net cash flow pose risks. Analyst sentiment is cautious with a majority Hold rating. Upside depends on stabilizing tenant operations and regulatory progress, while downside risks include further revenue pressure and sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Innovative Industrial Properties Inc
Innovative Industrial Properties Inc is a real estate investment trust engaged in the acquisition, ownership, and management of specialized industrial properties leased to state-licensed operators for their regulated medical-use cannabis facilities. It conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by Operating Partnership, directly or through subsidiaries. Its property portfolio is spread across the United States.
Read more on IIPR →
